CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
We are very excited to launch our new website! Please take a few moments to click around and explore...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...